New product launches and strong pharmaceutical sales have propelled Johnson & Johnson’s third-quarter net earnings to $4.3 billion on revenue of $17.8 billion. “With a number of regulatory approvals, several new drug application submissions and new breakthrough therapy designations from the FDA, we are increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over $1 billion,” said Alex Gorsky, Chairman and CEO of Johnson & Johnson. “Our broad-based business model, strategic investments and talented colleagues position us well for continued leadership in health care.” The company, which sells everything ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.